Physician profile
William C Summers
NPI 1265471650
$92,559.04
in general payments reported to CMS, 2019-2025
25 companies · $16K in 2025
The $16K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $8,868 · 2021: $9,245 · 2022: $13K · 2023: $17K · 2024: $6,125 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Travel and Lodging: $6,596 · Food and Beverage: $3,677 · Education: $54.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29,107.00 |
| Travel and Lodging | $6,596.16 |
| Food and Beverage | $3,677.22 |
| Education | $54.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $89,371.39 | 2019-2025 | Biktarvy, Sunlenca |
| Viiv Healthcare Company | $1,280.62 | 2019-2025 | Apretude, Dovato, Cabenuva |
| Astrazeneca Pharmaceuticals LP | $382.05 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $258.51 | 2019-2025 | Mavyret |
| Glaxosmithkline, LLC. | $243.69 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $240.87 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astellas Pharma US INC | $95.86 | 2025 | Veozah |
| Janssen Biotech, INC. | $93.23 | 2019 | |
| Emd Serono, INC. | $74.42 | 2023-2024 | Serostim |
| Lundbeck LLC | $69.07 | 2024-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $60.50 | 2019 | |
| Pfizer INC. | $53.91 | 2019 | |
| Antares Pharma, INC. | $47.71 | 2024-2025 | Xyosted |
| Takeda Pharmaceuticals U.S.A., INC. | $35.35 | 2019-2025 | Trintellix |
| Exact Sciences Corporation | $34.26 | 2023-2025 | Cologuard Collection Kit |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $30.04 | 2025 | Voquezna |
| Lilly USA, LLC | $29.98 | 2024-2025 | Mounjaro |
| Abbott Laboratories | $27.99 | 2024 | Cardiomems |
| Allergan, INC. | $24.37 | 2019 | |
| Theratechnologies INC. | $22.06 | 2023 | Egrifta, Trogarzo |
| Aimmune Therapeutics, INC. | $20.13 | 2025 | Vowst |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.50 | 2025 | Caplyta |
| Nestle Healthcare Nutrition INC. | $16.11 | 2023 | |
| Sanofi-Aventis U.S. LLC | $14.00 | 2019 | |
| Halozyme INC | $13.42 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Summers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.